Literature DB >> 21483020

Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.

Jeffrey N Roberts1, Rhonda C Kines, Hormuzd A Katki, Douglas R Lowy, John T Schiller.   

Abstract

BACKGROUND: Human papillomavirus (HPV) infection of the genital mucosa is thought to require trauma to the cervicovaginal epithelium. Therefore, we determined whether a cytology specimen collection procedure (Pap smear), which disrupts the epithelium by design, renders the cervix more susceptible to HPV infection in a primate model.
METHODS: In a series of female rhesus macaques, a speculum examination was performed with (n = 8) or without (n = 4) a cytology specimen collection procedure as it is commonly practiced in a gynecology clinic. An internal digital examination was performed after specimen collection using Surgilube (n = 4) or 1% iota-carrageenan, a previously indentified HPV inhibitor (n = 4) as the lubricant. The cervix was then inoculated with HPV16 pseudovirions expressing red fluorescent protein. After 3 days, the reproductive tracts were excised and the cervix was cryosectioned. Sections were analyzed by fluorescent confocal microscopy for the number of red fluorescent protein-positive keratinocytes.
RESULTS: Substantial infection of the ectocervix, the transformation zone, and the endocervix was detected, but only in conjunction with the cytology specimen collection procedure (cytology using Surgilube vs without cytology using Surgilube, mean = 84 infectious events per section vs mean = 0.05 infectious events per section, difference = 84 infectious events per section, 95% confidence interval = 19 to 384 infectious events per section). When the carrageenan gel was substituted for Surgilube for an internal digital examination, the mean number of infectious events decreased (carrageenan gel vs Surgilube, mean = 3.5 events per section vs mean = 84 infectious events per section difference = 81 events per section, 95% confidence interval = 33 to 213 events per section).
CONCLUSIONS: These findings indicate that cytology screening in women might lead to a transient enhancement of susceptibility to HPV infection and that use of a carrageenan-based gel during the examination might mitigate this enhancement.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21483020      PMCID: PMC3086876          DOI: 10.1093/jnci/djr061

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  24 in total

Review 1.  Histologic development of cervical ectopy: relationship to reproductive hormones.

Authors:  D L Jacobson; L Peralta; N M Graham; J Zenilman
Journal:  Sex Transm Dis       Date:  2000-05       Impact factor: 2.830

2.  Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.

Authors:  Sven-Eric Olsson; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Roger Maansson; Scott Vuocolo; Teresa M Hesley; Alfred Saah; Eliav Barr; Richard M Haupt
Journal:  Hum Vaccin       Date:  2009-10-01

3.  International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas.

Authors:  A P Vizcaino; V Moreno; F X Bosch; N Muñoz; X M Barros-Dios; D M Parkin
Journal:  Int J Cancer       Date:  1998-02-09       Impact factor: 7.396

4.  Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

Authors:  C B Woodman; S Collins; H Winter; A Bailey; J Ellis; P Prior; M Yates; T P Rollason; L S Young
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

5.  Variations in vaginal epithelial surface appearance determined by colposcopic inspection in healthy, sexually active women.

Authors:  I S Fraser; P Lähteenmäki; K Elomaa; M Lacarra; D R Mishell; F Alvarez; V Brache; E Weisberg; M Hickey; P Vallentine; H A Nash
Journal:  Hum Reprod       Date:  1999-08       Impact factor: 6.918

6.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.

Authors:  H O Smith; M F Tiffany; C R Qualls; C R Key
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

7.  Cervical cancer mortality in young women in Europe: patterns and trends.

Authors:  F Levi; F Lucchini; E Negri; S Franceschi; C la Vecchia
Journal:  Eur J Cancer       Date:  2000-11       Impact factor: 9.162

8.  Prevalence of HPV infection among females in the United States.

Authors:  Eileen F Dunne; Elizabeth R Unger; Maya Sternberg; Geraldine McQuillan; David C Swan; Sonya S Patel; Lauri E Markowitz
Journal:  JAMA       Date:  2007-02-28       Impact factor: 56.272

9.  Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival.

Authors:  Mark E Sherman; Sophia S Wang; Joseph Carreon; Susan S Devesa
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

10.  Carrageenan is a potent inhibitor of papillomavirus infection.

Authors:  Christopher B Buck; Cynthia D Thompson; Jeffrey N Roberts; Martin Müller; Douglas R Lowy; John T Schiller
Journal:  PLoS Pathog       Date:  2006-07       Impact factor: 6.823

View more
  23 in total

1.  Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Authors:  Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

2.  The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.

Authors:  Meropi Aravantinou; Rachel Singer; Nina Derby; Giulia Calenda; Paul Mawson; Ciby J Abraham; Radhika Menon; Samantha Seidor; Daniel Goldman; Jessica Kenney; Guillermo Villegas; Agegnehu Gettie; James Blanchard; Jeffrey D Lifson; Michael Piatak; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova; Melissa Robbiani
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

3.  Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial.

Authors:  S Magnan; J E Tota; M El-Zein; A N Burchell; J T Schiller; A Ferenczy; P-P Tellier; F Coutlée; E L Franco
Journal:  Clin Microbiol Infect       Date:  2018-04-21       Impact factor: 8.067

4.  Genital delivery of virus-like particle and pseudovirus-based vaccines.

Authors:  Nicolas Cuburu; Bryce Chackerian
Journal:  Expert Rev Vaccines       Date:  2011-09       Impact factor: 5.217

5.  Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.

Authors:  Nicolas Çuburu; Barney S Graham; Christopher B Buck; Rhonda C Kines; Yuk-Ying S Pang; Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

Review 6.  Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential.

Authors:  Vikrant V Sahasrabuddhe; Groesbeck P Parham; Mulindi H Mwanahamuntu; Sten H Vermund
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-12

7.  Spontaneous cervicovaginal lesions and immune cell infiltrates in nonhuman primates.

Authors:  Carole E Harbison; Mary E Ellis; Susan V Westmoreland
Journal:  Toxicol Pathol       Date:  2013-02-20       Impact factor: 1.902

8.  In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel.

Authors:  Akiva P Novetsky; Marla J Keller; Ana Gradissimo; Zigui Chen; Stephanie L Morgan; Xiaonan Xue; Howard D Strickler; José A Fernández-Romero; Robert Burk; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2016-09-10       Impact factor: 5.482

Review 9.  L2, the minor capsid protein of papillomavirus.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Virology       Date:  2013-05-17       Impact factor: 3.616

10.  Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.

Authors:  Nicolas Çuburu; Selina Khan; Cynthia D Thompson; Rina Kim; Jort Vellinga; Roland Zahn; Douglas R Lowy; Gert Scheper; John T Schiller
Journal:  Int J Cancer       Date:  2017-12-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.